Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

A 69-year-old woman was referred to the retina service for abnormal posterior segment findings.The patient’s medical history ...

Age-related macular degeneration (AMD), classified into dry and wet types, poses a significant threat to the vision of the ...

A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

Whether you’re a latte lover, a mocha monster or an espresso elitist — people have strong preferences when it comes to coffee ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Cataract surgery is the most commonly performed eye surgery in the ophthalmology, with a track record of improving vision and ...

Researchers in a new study learned that consuming this specific type of coffee may substantially increase a person’s risk of ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

How you prepare your morning cup of joe could be linked to an eye disease that affects nearly 20 million Americans.